Multiple SclerosisVAMOS-MSNCT07606742
Delivery of a Culturally Tailored Exercise Training Intervention for Hispanics With Multiple Sclerosis
A study testing Exercise Training in people with Multiple Sclerosis, run by The University of Texas Health Science Center, Houston at 1 site in United States.
Trial summary
The purpose of this study is to establish differences in the primary outcome of walking dysfunction using the 12-Item Multiple Sclerosis Walking Scale (MSWS-12) and to establish differences in the secondary outcome of HRQoL using the 29-Item Multiple Sclerosis Walking Scale (MSWS-29) between the exercise training… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Multiple Sclerosis
- What is being tested?
- Exercise Training
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 66 participants
- Where
- 1 siteUnited States
- Study dates
- 24 Aug 2026to 31 Oct 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- diagnosis of MS
- relapse-free in the past 30 days
- self-identify as Hispanic/Latino
- Patient Determined Disease Steps Scale (PDDS) score between 3.0 (gait disability) and 6.0 (bilateral support) indicates walking disability.
- MSWS-12 score between 25 and 75, indicating walking disability
- Willingness to complete the questionnaires and undergo randomization
- English or Spanish as a primary language
Who cannot join
- significant exercise-related risk factors or contraindications, assessed individually using the Physical Activity Readiness Questionnaire (PAR-Q; requires clearance from physician).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
The University of Texas Health Science Center at Houston
Houston, Texas, 77030
Stephanie L Silveira, PhD, (713) 500-9000, Stephanie.L.Silveira@uth.tmc.edu
Najha Black, 713-500-9154, Najha.C.Marshall@uth.tmc.edu
About this study
The purpose of this study is to establish differences in the primary outcome of walking dysfunction using the 12-Item Multiple Sclerosis Walking Scale (MSWS-12) and to establish differences in the secondary outcome of HRQoL using the 29-Item Multiple Sclerosis Walking Scale (MSWS-29) between the exercise training intervention condition and the waitlist control condition following the 16-week intervention period.
- Conditions
- Multiple Sclerosis
- Being tested
- Exercise Training
- Keywords
- Exercise training, mobility disability, implementation
- Medical subject headings
- Multiple Sclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Exercise TrainingBehavioural
Participants will then be mailed exercise materials in their preferred language, including the program manual, logbook, calendar, newsletters, Fitbit, and resistance bands, along with instructions for telephone or video conference calls. This is a 16-week, home-based program, supported remotely via Internet-based behavioral coaching, which integrates behavior change techniques based on Social Cognitive Theory (SCT)
| Study group | Role | What they receive |
|---|---|---|
| Exercise Training | Experimental | Not described Receives: Behavioral: Exercise Training |
| Waitlist Control | No intervention | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in walking ability as assessed by the 12-Item Multiple Sclerosis Walking Scale (MSWS-12)
This is a 12 item questionnaire and each is scored on a 5-point Likert scale from 1(not at all) to 5(extremely). Total raw scores ranging from 12-60 are converted into standardized scores from 0-100, with higher scores indicating greater perceived walking impairment related to multiple sclerosis.
Measured: Baseline, 16 weeks, 32 weeks
Secondary outcomes (1)
Change in HRQoL as assessed by the 29-Item Multiple Sclerosis Walking Scale (MSWS-29)
This is a 29 item questionnaire and each is scored from 1( not at all) to 5(extremely) , with a Raw score range from 29 to 145. This is then converted into a standardized scale from 0 to 100, with higher scores indicating worse walking impairment and greater impact of multiple sclerosis on mobility.
Measured: Baseline, 16 weeks, 32 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 May 2026
- Study start24 Aug 2026
- Primary completion30 Jun 2028 (estimated)
- Study completion31 Oct 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple SclerosisStudies of the same condition, open and under way.
- More trials run by The University of Texas Health Science Center, HoustonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 66 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Collaborators
- National Institutes of Health (NIH)
- Responsible party
- Principal investigator, Stephanie Lee Silveira, The University of Texas Health Science Center, Houston
- Investigators
- Stephanie L Silveira, PhD, Principal investigator, The University of Texas Health Science Center, Houston
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07606742
- Sponsor's protocol ID
- HSC-SPH-25-0341
- Acronym
- VAMOS-MS
- Status last verified
- Sep 2026
- First submitted
- 18 May 2026
- Last updated
- 17 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Delivery of a Culturally Tailored Exercise Training Intervention for Hispanics With Multiple Sclerosis
- ClinicalTrials.gov ID
- NCT07606742
- Acronym / sponsor ID
- VAMOS-MS / HSC-SPH-25-0341
- Conditions
- Multiple Sclerosis
- Keywords
- Exercise training, mobility disability, implementation
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 66 participants (estimated)
- Lead sponsor
- The University of Texas Health Science Center, HoustonUniversity, hospital or other
- Collaborators
- National Institutes of Health (NIH)
- Study start
- 24 Aug 2026 (actual)
- Primary completion
- 30 Jun 2028 (estimated)
- Study completion
- 31 Oct 2028 (estimated)
- First posted
- 26 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to establish differences in the primary outcome of walking dysfunction using the 12-Item Multiple Sclerosis Walking Scale (MSWS-12) and to establish differences in the secondary outcome of HRQoL using the 29-Item Multiple Sclerosis Walking Scale (MSWS-29) between the exercise training intervention condition and the waitlist control condition following the 16-week intervention period.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Exercise Training | Experimental | Behavioral: Exercise Training |
| Waitlist Control | No intervention | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- diagnosis of MS
- relapse-free in the past 30 days
- self-identify as Hispanic/Latino
- Patient Determined Disease Steps Scale (PDDS) score between 3.0 (gait disability) and 6.0 (bilateral support) indicates walking disability.
- MSWS-12 score between 25 and 75, indicating walking disability
Key exclusion criteria (1 listed)
- significant exercise-related risk factors or contraindications, assessed individually using the Physical Activity Readiness Questionnaire (PAR-Q; requires clearance from physician).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Exercise TrainingParticipants will then be mailed exercise materials in their preferred language, including the program manual, logbook, calendar, newsletters, Fitbit, and resistance bands, along with instructions for telephone or video conference calls. This is a 16-week, home-based program, supported remotely via Internet-based behavioral coaching, which integrates behavior change techniques based on Social Cognitive Theory (SCT) | Behavioural | Exercise Training |
Primary outcome
Change in walking ability as assessed by the 12-Item Multiple Sclerosis Walking Scale (MSWS-12)
Time frame: Baseline, 16 weeks, 32 weeks
This is a 12 item questionnaire and each is scored on a 5-point Likert scale from 1(not at all) to 5(extremely). Total raw scores ranging from 12-60 are converted into standardized scores from 0-100, with higher scores indicating greater perceived walking impairment related to multiple sclerosis.
1 secondary outcome
Change in HRQoL as assessed by the 29-Item Multiple Sclerosis Walking Scale (MSWS-29)
Time frame: Baseline, 16 weeks, 32 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Sep 2026.
Related trials for Multiple Sclerosis
RecruitingPhase 2
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
Multiple Sclerosis
RecruitingObservational study
Pain Phenotypes in Individuals With Multiple Sclerosis
Multiple Sclerosis, Chronic Pain
Not yet recruiting
Evaluating the Effect of the Zeen Mobility Device on Clinical Practicality, Safety, and Impact (Via Assessments of Walking, Standing Tolerance, Balance, Endurance, Effort, and Participation in Daily Tasks) in an Outpatient Rehabilitation Setting for Individuals With Mobility Impairments.
Stroke, Parkinson's Disease (PD)
RecruitingPhase 3
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
Multiple Sclerosis
RecruitingPhase 2
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
Multiple Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Stephanie L Silveira, PhD principal investigator
The University of Texas Health Science Center, Houston
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Exercise Training in people with Multiple Sclerosis, run by The University of Texas Health Science Center, Houston at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 17 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Stephanie L Silveira, PhD ((713) 500-9490, Stephanie.L.Silveira@uth.tmc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in walking ability as assessed by the 12-Item Multiple Sclerosis Walking Scale (MSWS-12) (time frame: Baseline, 16 weeks, 32 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Sep 2026.